News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA: Authorities Seize Unapproved Crescendo Therapeutics Drug


5/23/2012 7:38:28 AM

For months, Crescendo Therapeutics appears to have been thumbing its corporate nose at the FDA. Last November, the agency warned the little company for failing to maintain a system for collecting adverse event reports for its HybriSil topical treatment for scars. Crescendo offered a novel explanation – side effect reports simply had not been received (back story). Moreover, the FDA upbraided Crescendo for marketing HybriSil in the first place – the product, you see, was never approved.

Read at Pharmalot
Read at PharmaLive
Read at FDA
Read at Wall Street Journal

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES